Latest news with #imetelstat
Business Upturn
2 days ago
- Business
- Business Upturn
Geron Corporation Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Geron Corporation ('Geron' or 'the Company') (NASDAQ: GERN) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Geron investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Advertisement Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. The Complaint alleges that, throughout the Class Period, Defendants provided investors with material information regarding the anticipated launch and growth potential of Rytelo (imetelstat). Specifically, the Complaint asserts that Defendants repeatedly expressed confidence in Geron's ability to capitalize on the purportedly significant unmet medical need for the drug and to execute its commercial plan targeting first-line ESA-ineligible patients, while downplaying or minimizing risks associated with the weekly monitoring requirements for Rytelo, as well as the potential impacts of seasonality and competition on the drug's sales. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq. Admitted CA, NY and TX Bars [email protected] 310-692-8883 Attorney Advertising Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Malaysian Reserve
06-05-2025
- Business
- Malaysian Reserve
Geron Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights
NEW YORK, May 6, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Geron Corporation ('Geron' or the 'Company') (NASDAQ: GERN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team: GERN investors may also contact Joseph E. Levi, Esq. via email at jlevi@ or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning defendants' expectations for the launch and growth potential of Rytelo (imetelstat). Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales. On February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo's growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. Following this news, the price of Geron's common stock declined dramatically. From a closing market price of $2.37 per share on February 25, 2025, Geron's stock price fell to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Geron during the relevant time frame, you have until May 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 jlevi@ Tel: (212) 363-7500 Fax: (212) 363-7171 View original content to download multimedia: SOURCE Levi & Korsinsky, LLP
Associated Press
17-03-2025
- Business
- Associated Press
GERN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the 'Class Period'), have until May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron and certain of Geron's top current and former executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Potvin v. Geron Corporation, No. 25-cv-02563 (N.D. Cal.). If you suffered substantial losses and wish to serve as lead plaintiff of the Geron class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Geron is a commercial-stage biopharmaceutical company that focuses on the development of therapeutic products for oncology. According to the complaint, Geron's primary product is a telomerase inhibitor, imetelstat, which Geron sells under the brand name Rytelo. The Geron class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Geron's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations; (ii) in truth, Geron's optimistic reports of Rytelo's launch success and potential growth fell short of reality as the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than defendants had implied; and (iii) Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting. The Geron class action lawsuit further alleges that on February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal year 2024, disclosing that Rytelo's growth had flattened over the preceding months, attributing the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, Geron's stock price declined more than 32%, the complaint alleges. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Geron securities during the Class Period to seek appointment as lead plaintiff in the Geron class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Geron class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Geron Energy class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Geron class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal
Associated Press
15-03-2025
- Business
- Associated Press
GERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, both dates inclusive (the 'Class Period'), have until May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron and certain of Geron's top current and former executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Potvin v. Geron Corporation, No. 25-cv-02563 (N.D. Cal.). If you suffered substantial losses and wish to serve as lead plaintiff of the Geron class action lawsuit, please provide your information here: CASE ALLEGATIONS: Geron is a commercial-stage biopharmaceutical company that focuses on the development of therapeutic products for oncology. According to the complaint, Geron's primary product is a telomerase inhibitor, imetelstat, which Geron sells under the brand name Rytelo. The Geron class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Geron's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations; (ii) in truth, Geron's optimistic reports of Rytelo's launch success and potential growth fell short of reality as the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than defendants had implied; and (iii) Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting. The Geron class action lawsuit further alleges that on February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal year 2024, disclosing that Rytelo's growth had flattened over the preceding months, attributing the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, Geron's stock price declined more than 32%, the complaint alleges. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Geron securities during the Class Period to seek appointment as lead plaintiff in the Geron class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Geron class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Geron class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Geron class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 SOURCE: Robbins Geller Rudman & Dowd LLP Copyright Business Wire 2025. PUB: 03/15/2025 10:20 AM/DISC: 03/15/2025 10:20 AM
